Core Viewpoint - Class action lawsuits have been filed against several publicly-traded companies, alleging that these companies made materially false and misleading statements regarding their business operations and financial prospects, which have adversely affected shareholders [1]. Company Summaries Molina Healthcare, Inc. (NYSE: MOH) - Class Period: February 5, 2025 – July 23, 2025 - Allegations include failure to disclose adverse facts about medical cost trend assumptions and a dislocation between premium rates and medical costs, leading to a likely cut in financial guidance for fiscal year 2025 [2]. Marex Group plc (NASDAQ: MRX) - Class Period: May 16, 2024 – August 5, 2025 - Allegations include selling over-the-counter financial instruments to itself and inconsistencies in financial statements, making the financial data unreliable [3]. aTyr Pharma Inc. (NASDAQ: ATYR) - Class Period: November 7, 2024 – September 12, 2025 - Allegations include misleading statements regarding the study design for EFZO-FIT and the failure to meet primary endpoints, which misrepresented the company's prospects [4]. WPP plc (NYSE: WPP) - Class Period: February 27, 2025 – July 8, 2025 - Allegations include the media arm's inability to handle macroeconomic challenges and loss of market share, rendering positive statements about the company's operations misleading [6].

Core Viewpoint - Molina Healthcare, Inc. is facing a class action securities lawsuit due to alleged securities fraud that negatively impacted investors between February 5, 2025, and July 23, 2025 [1][2]. Group 1: Allegations and Impact - The lawsuit claims that defendants made false statements and concealed material adverse facts regarding the company's medical cost trend assumptions [2]. - It is alleged that Molina was experiencing a dislocation between premium rates and medical cost trends, which could lead to a significant cut in the company's financial guidance for fiscal year 2025 [2]. - The lawsuit suggests that Molina's near-term growth relied on a lack of utilization of behavioral health, pharmacy, and inpatient and outpatient services, which misled investors about the company's business prospects [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until December 2, 2025, to request to be appointed as lead plaintiff in the case [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, and participation does not require serving as a lead plaintiff [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

Core Viewpoint - Rosen Law Firm is encouraging investors of Molina Healthcare, Inc. to secure legal counsel before the December 2, 2025 deadline for a securities class action lawsuit related to undisclosed adverse facts affecting the company's financial guidance and operations [1][5]. Group 1: Class Action Details - Investors who purchased Molina securities between February 5, 2025, and July 23, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by December 2, 2025 [3]. - The lawsuit alleges that Molina failed to disclose critical information regarding its medical cost trend assumptions and the impact on its financial guidance for fiscal year 2025 [5]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [4]. - The Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions for investors [4]. Group 3: Case Specifics - The lawsuit claims that Molina's near-term growth was reliant on a lack of utilization of various health services, which was not disclosed to investors [5]. - The misleading positive statements made by Molina regarding its business operations and prospects are central to the claims in the lawsuit [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Molina Healthcare, Inc. securities between February 5, 2025, and July 23, 2025, of the December 2, 2025, deadline to become lead plaintiffs in a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Molina securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 2, 2025 [2]. - The lawsuit alleges that Molina failed to disclose several material adverse facts regarding its financial health and operational assumptions, which misled investors [4]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering significant amounts for investors [3]. - The firm has been recognized for its leadership in securities class action settlements, achieving notable recoveries, including over $438 million in 2019 alone [3]. Group 3: Case Specifics - The lawsuit claims that Molina's financial guidance for fiscal year 2025 was likely to be cut due to undisclosed adverse facts, which included issues with medical cost trend assumptions and a dislocation between premium rates and medical costs [4]. - The misleading positive statements made by Molina regarding its business operations and prospects are central to the claims made in the lawsuit [4].

Core Viewpoint - Molina Healthcare, Inc. is facing a class action lawsuit due to allegations of false statements and concealment of material facts regarding its financial health and operational assumptions, which led to a significant drop in its stock price [3]. Summary by Sections Class Action Details - The class period for the lawsuit is from February 5, 2025, to July 23, 2025 [3]. - Allegations include misleading statements about the company's medical cost trend assumptions and the dislocation between premium rates and medical costs [3]. Financial Implications - The lawsuit claims that Molina's near-term growth relied on reduced utilization of various health services, which could lead to a substantial cut in financial guidance for fiscal year 2025 [3]. Shareholder Actions - Shareholders are encouraged to register for the class action by December 2, 2025, to potentially become lead plaintiffs and participate in recovery efforts [4]. - Registration provides access to portfolio monitoring software for updates on the case [4]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5].

Core Insights - President Trump is expected to announce a plan to extend Affordable Care Act (ACA) subsidies, which has led to a surge in shares of major health insurers [1][5] - The proposed plan may extend ACA subsidies for approximately two years and could introduce new income limits for enrollees, along with minimum premium payments [1][2] Group 1: Market Reaction - Shares of Molina Healthcare (MOH) increased by over 3%, Centene (CNC) rose by 5%, and Oscar Health (OSCR) saw an 18% jump following the news [1] - The potential extension of subsidies is anticipated to stabilize enrollment and reduce volatility in the individual health insurance market [2] Group 2: Legislative Context - The ACA subsidies were a contentious issue during the recent government shutdown, with Democratic lawmakers blocking funding bills to extend these subsidies [3] - The White House plans to request Congress to approve funds aimed at reducing cost-sharing, which would lower out-of-pocket expenses for some ACA recipients [2]

Core Points - Class action lawsuits have been filed on behalf of shareholders of several publicly-traded companies, with specific deadlines for filing lead plaintiff motions [1] Company Summaries Molina Healthcare, Inc. (NYSE: MOH) - Class Period: February 5, 2025 – July 23, 2025 - Allegations include false and misleading statements regarding medical cost trend assumptions, dislocation between premium rates and medical costs, and reliance on reduced utilization of services, leading to likely cuts in financial guidance for fiscal year 2025 [2] Marex Group plc (NASDAQ: MRX) - Class Period: May 16, 2024 – August 5, 2025 - Allegations include selling over-the-counter financial instruments to itself, inconsistencies in financial statements, and reliance issues with financial statements, resulting in misleading positive statements about the company's operations and prospects [3] WPP plc (NYSE: WPP) - Class Period: February 27, 2025 – July 8, 2025 - Allegations include the media arm's inability to handle macroeconomic challenges and loss of market share, leading to misleading positive statements about the company's business and operations [4]

Core Viewpoint - U.S. health insurers' shares surged following reports of a potential two-year extension of Affordable Care Act (ACA) premium subsidies, which would alleviate concerns over premium increases and enrollment declines [1][3]. Group 1: Company Reactions - Centene's shares increased by approximately 7%, Molina Healthcare's shares rose around 4%, and Elevance Health's shares climbed more than 2% in early trading [1]. - Hospital operators also saw positive movements, with HCA Healthcare shares rising by 3.2%, Universal Health Services up nearly 2%, and Tenet Healthcare jumping 6% [4]. Group 2: Market Sentiment - The anticipated two-year extension is viewed as a "better than feared" scenario for health insurers, providing relief after uncertainty surrounding ACA subsidies [2]. - Investors had been cautious due to the potential expiration of pandemic-era enhanced tax credits, but public support for extending these credits remains strong, with about three-quarters of U.S. adults favoring renewal [6]. Group 3: Industry Implications - The proposed policy framework is expected to ease risks associated with sharp premium increases and potential enrollment declines in 2026, thereby improving healthcare affordability [3]. - Analysts suggest that the proposals, although still in early stages, would be favorable for healthcare services, including hospitals and managed care businesses [4].

Accessibility StatementSkip Navigation NEW YORK, Nov. 24, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Molina Healthcare, Inc. (NYSE: MOH). Shareholders who purchased shares of MOH during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/molina-healthcare-inc-loss-submission-form/ ...

Core Insights - Molina Healthcare, Inc. is a significant player in the U.S. managed care sector, focusing on health insurance for individuals and families under government programs, with a market cap of $7.7 billion [1] Stock Performance - Molina shares have experienced a significant decline of 52.2% over the past year, contrasting sharply with the S&P 500 Index, which gained 11% during the same period [2] - In the last six months, Molina's stock plummeted 55.7%, while the S&P 500 Index rose by 13% [2] Industry Comparison - Within the healthcare sector, Molina's performance has lagged behind the SPDR S&P Health Care Services ETF, which increased by 12.5% over the past year and 8.6% over the past six months [3] Financial Results - For Q3 2025, Molina reported a revenue increase of 11% year over year, reaching $11.5 billion, but adjusted EPS fell dramatically by 69.4% to $1.84 [4] - The consolidated medical care ratio rose to 92.6%, primarily due to higher costs in the ACA segment [4] - Membership grew to 5.6 million, but this was insufficient to alleviate profit concerns [4] Earnings Guidance - Molina has revised its full-year adjusted EPS guidance down to approximately $14, a significant drop from earlier expectations of around $19, marking the third guidance reduction of the year [4] - Analysts project a 38.4% year-over-year decline in EPS for the current fiscal year, estimating it at $13.95 on a diluted basis [5] Analyst Sentiment - The consensus rating for Molina's stock is "Hold," with 18 analysts providing recommendations: 3 suggest "Strong Buy," 12 recommend "Hold," 1 has a "Moderate Sell," and 2 advise a "Strong Sell" [6]